Long-term antibiotic treatment creates a peculiar milestone in chronic illness communities that receives surprisingly little scientific scrutiny: becoming “antibiotic-free.”
The phrase sounds like recovery. After months or years of prescriptions, an empty medication bottle can seem to mark the end of something difficult and unwanted. Patients remember their last dose, count the months since treatment, and sometimes speak of stopping antibiotics almost as a graduation.
Given the real risks and burdens of prolonged antimicrobial therapy, the desire to reach that point is understandable. Antibiotics can cause adverse effects, alter microbial communities, interact with other medications and, particularly when administered intravenously, expose patients to complications related to vascular access. Nobody should romanticize years of treatment.
Yet there is another side to this story that is discussed far less often. For some patients, discontinuing antibiotics does not coincide with sustained recovery. Fatigue returns. Cognitive function deteriorates. Pain becomes more intrusive. Skin symptoms recur. The ability to work or participate in family life slowly erodes. Sometimes a clinician restarts treatment, the patient improves, and both enter a cycle that neither the language of “cure” nor the language of “treatment failure” adequately describes.
This creates an uncomfortable question for medicine: What if an antibiotic is not producing a durable cure but is nevertheless helping a patient function?
When “Antibiotic-Free” Becomes a Measure of Success
For patients who have taken antibiotics for months or years, this is more than an academic debate. Long-term treatment can acquire a surprisingly moralistic language. People often frame being “off antibiotics” as success, while continued treatment can make a patient feel as though they failed to recover correctly. Patients may begin to apologize for their medication histories or conceal the length of treatment from new clinicians because they already know the reaction the answer may provoke.
But patients should not be ashamed of the treatment they needed to remain functional. Some people stop antibiotics and continue to improve. Others relapse, while a third group cycles between treatment and decline. For still others, continued therapy—despite its risks and limitations—may provide a quality of life they cannot maintain without it.
These patterns deserve measurement rather than moral judgment.
A patient who still requires treatment has not failed.
Long-Term Antibiotic Treatment Is Already Common
Before debating whether prolonged antibiotics are beneficial, it is worth acknowledging how many chronically ill Lyme patients report already receiving them.
A 2020 peer-reviewed analysis of respondents in the MyLymeData patient registry examined antibiotic treatment response among people who identified as having chronic Lyme disease and remained ill after initial treatment. Among antibiotic-treated respondents, 57% reported receiving antibiotics for four months or longer, while 32% reported treatment lasting more than one year. Only 19% reported less than one month of antibiotic therapy.
The study also linked longer treatment duration with better patient-reported treatment response. Patients classified as high responders or well appeared disproportionately among those reporting longer courses.
What the Registry Data Can—and Cannot—Tell Us
These findings are provocative, but their limitations are equally important. The researchers analyzed an observational registry built from patient-reported experience; they did not randomly assign comparable patients to predefined treatment durations. It therefore cannot establish that additional months or years of antibiotics caused better outcomes.
There are obvious alternative explanations. Patients who improve substantially may remain on therapy precisely because treatment appears to help, while those who gain little benefit or develop intolerable adverse effects may stop earlier. Clinicians willing to provide longer treatment may use different combinations of medications or pursue coexisting diagnoses more aggressively. Disease severity, time to diagnosis, concurrent treatments and access to specialty care may differ between groups.
This is the familiar problem of confounding by indication and treatment response: the reason a patient remains on therapy may itself be related to the outcome being measured.
Why the Treatment Duration Numbers Still Matter
Still, the numbers matter for another reason. When nearly one-third of antibiotic-treated respondents in a large patient registry report more than a year of therapy, long-duration treatment can no longer be dismissed as a fringe theoretical practice involving a handful of unusually aggressive clinicians. Whether one believes treatment helps these patients, harms them, or exposes them to therapy without sufficient evidence, clinicians and patients are already making these decisions.
Researchers should study this pattern rigorously.
What happens to physical function during prolonged treatment? How do fatigue, cognition, pain and the ability to work change? Which benefits, when present, persist after treatment withdrawal, and which disappear? Can researchers distinguish responders from nonresponders before months of treatment pass?
Simply asking how quickly patients can be taken off antibiotics avoids the more difficult clinical question: what happens to the patient when we do?
The Randomized Trials Tell a More Complicated Story Than Either Side Admits
The controversy surrounding persistent symptoms after Lyme disease has produced two remarkably durable slogans. One is that prolonged antibiotics “do not work.” The other is that long-term antibiotics are necessary because persistent infection is responsible for ongoing illness.
Neither statement, presented without qualification, captures the clinical trial literature.
Randomized retreatment studies have not shown that prolonged antibiotic therapy reliably produces sustained, generalized recovery in patients with persistent symptoms after Lyme disease treatment. That conclusion matters and should be stated without evasion.
Klempner and PLEASE: Important Negative Trials
In 2001, Klempner and colleagues published two placebo-controlled trials involving seropositive and seronegative patients with persistent symptoms following previously treated Lyme disease. Participants received 30 days of intravenous ceftriaxone followed by 60 days of oral doxycycline, or matching placebos. After 90 days of antimicrobial treatment, the investigators found no significant improvement over placebo in the principal measures of health-related quality of life.
The PLEASE trial, published in 2016, likewise failed to demonstrate an additional health-related quality-of-life benefit from a longer antibiotic strategy. Researchers first gave all participants two weeks of intravenous ceftriaxone, then randomized them to 12 weeks of doxycycline, clarithromycin plus hydroxychloroquine, or placebo. On the study’s primary quality-of-life outcome, the additional oral antibiotic regimens did not outperform placebo.
These are not studies the Lyme community should pretend do not exist. They challenge the idea that simply extending antibiotic duration will predictably produce sustained recovery across a broad population of patients with persistent symptoms.
A Negative Average Does Not Mean Nothing Happened
But there is an equally important scientific mistake on the other side of the debate: converting the absence of a consistent, durable group-level benefit into the much broader declaration that antibiotics have demonstrated no measurable clinical effect in persistent Lyme-associated illness.
That is not what every randomized trial found.
The distinction matters because clinical trials answer the questions they were designed to ask. A heterogeneous study population can hide a subgroup response inside a neutral average. One treatment may improve a single domain while leaving others unchanged. During therapy, benefits may appear and then disappear after withdrawal. A study may correctly conclude that a treatment strategy does not merit routine recommendation because its risks outweigh its overall benefits while still documenting a real treatment-associated change in a particular outcome.
This is not an argument for ignoring negative trials. It is an argument for reading the entire trial rather than only its final sentence.
The STOP-LD Trial and the Problem of “Only Fatigue”
The 2003 STOP-LD trial provides a useful example. Researchers enrolled patients with persistent severe fatigue following previously treated Lyme disease and randomized them to 28 days of intravenous ceftriaxone or placebo.
Patients who received ceftriaxone improved in fatigue, the study’s primary clinical outcome. It did not produce significant improvement in cognitive measures or an experimental laboratory marker of infection. Patients also experienced adverse events during treatment. The investigators therefore concluded that the study did not support additional parenteral ceftriaxone therapy in persistently fatigued patients with post-Lyme syndrome.
It is entirely reasonable to discuss why the researchers reached that recommendation. Intravenous treatment carries risks, and an improvement limited largely to fatigue may not justify those risks at a population level.
What is less reasonable is allowing the clinical outcome itself to disappear from the discussion. Patients receiving antibiotics improved in fatigue.
Nonspecific Does Not Mean Clinically Unimportant
Fatigue is nonspecific. It can arise from infection, inflammation, sleep disorders, endocrine disease, anemia, medications, depression, autonomic dysfunction and many other causes. An improvement in fatigue therefore does not identify the mechanism responsible for a patient’s illness, nor does it prove that viable Borrelia burgdorferi persisted after prior treatment.
Yet “nonspecific” is a description of diagnostic specificity, not a measurement of human importance.
Severe fatigue can determine whether a person works full time, works at all, prepares a meal, takes a shower, follows a conversation or participates meaningfully in family life. In quality-of-life research, the fact that an outcome is subjective or etiologically nonspecific does not make it clinically irrelevant. Pain is also nonspecific. So are sleep disturbance and exercise intolerance. Medicine routinely attempts to improve such outcomes because human function is itself a legitimate therapeutic endpoint.
The intellectually interesting question raised by STOP-LD is therefore not whether 28 days of intravenous ceftriaxone should be routinely prescribed for persistent fatigue. The investigators themselves concluded that it should not.
The more interesting question is why fatigue improved in the antibiotic-treated group and whether the same benefit could ever be predicted, reproduced or achieved more safely in a defined subgroup of patients.
A recommendation against routine use is not the same as evidence that nothing happened.
The Fallon Trial and What Happened After Treatment Stopped
The 2008 randomized trial led by Brian Fallon is even more difficult to fit into a simple narrative.
The study enrolled patients who had physician-documented Lyme disease, previous intravenous antibiotic treatment, current positive IgG Western blot results and objective memory impairment. Participants received ten weeks of intravenous ceftriaxone or placebo and underwent serial neurocognitive and clinical assessment.
At week 12, the ceftriaxone-treated patients demonstrated greater cognitive improvement than placebo recipients when performance was adjusted for baseline differences. By week 24, however, the cognitive advantage was no longer sustained. The investigators concluded that intravenous ceftriaxone produced short-term cognitive improvement but that cognition relapsed after patients discontinued the antibiotic.
The Benefit Was Not the Whole Story
Other clinical outcomes were more nuanced. Among patients with greater baseline impairment, the trial documented improvement in some measures of pain, physical functioning and fatigue, although durability varied by outcome and subgroup. At the same time, adverse events related to either the study medication or PICC line occurred in 6 of 23 ceftriaxone recipients, or 26.1%, compared with 1 of 14 placebo recipients.
This is exactly the kind of result that should make both sides of the Lyme debate uncomfortable.
The trial did not demonstrate a durable cognitive cure. Ten weeks of ceftriaxone did not permanently reverse the illness being studied. The adverse-event rate also makes it difficult to argue that repeated intravenous treatment should be casually or routinely offered.
But cognition improved during treatment, and patients lost that advantage after treatment ended.
A Treatment Response Does Not Prove Persistence
That temporal pattern does not prove persistent bacterial infection. A clinical response to an antibiotic cannot, by itself, establish microbial persistence. Antibiotics may have immunomodulatory or anti-inflammatory effects; symptoms may fluctuate; multiple biological processes may be occurring simultaneously. Even a genuine pharmacologic response does not automatically identify the mechanism of that response.
Still, the finding deserves more intellectual curiosity than the sentence “long-term antibiotics don’t work.” Something measurable changed during treatment. Patients did not sustain the cognitive advantage after treatment ended. The difficult question is what that pattern means.
If function improves during therapy and declines again after withdrawal, is discontinuing treatment automatically the successful outcome?
Cure Is Not the Only Model Medicine Uses
Modern infectious disease is often explained through a clean therapeutic narrative. A pathogen causes disease. A drug with activity against that pathogen is selected. The organism is eradicated. Treatment stops. The patient recovers.
For many infections, that model works extraordinarily well. It is one of medicine’s greatest achievements.
It is not, however, the only way antimicrobial therapy is used.
In selected persistent infections where definitive eradication is difficult or the intervention required for cure is not feasible, clinicians sometimes use chronic suppressive antibiotic therapy. Prosthetic joint infection offers one established example of the concept. Because infected prosthetic material can be extraordinarily difficult to sterilize without surgical source control, some patients who cannot undergo or decline further surgery receive prolonged antimicrobial suppression.
A 2022 retrospective cohort of 45 prosthetic joint infections treated with chronic antibiotic suppression reported that 30 infections, or 67%, were managed without reoperation or infection-related death during a median follow-up of approximately 50 months. The authors described chronic antibiotic suppression as a reasonable strategy for selected patients who lacked or declined further surgical options.
The Comparison Is Conceptual, Not Diagnostic
A prosthetic joint infection is not Lyme disease, and this comparison must not be stretched beyond its purpose. Evidence supporting suppressive therapy in one infection does not establish that persistent symptoms after Lyme disease represent ongoing infection or that the same treatment philosophy should simply be imported into Lyme care.
The point is conceptual.
Medicine already understands that antimicrobial treatment does not always exist exclusively in the categories of cure or failure. Under defined circumstances, clinicians may control an infection rather than eradicate it. Clinicians may continue treatment because they expect the patient to fare better with suppression than without it. Clinicians then shift the goal from sterilizing cure to maintaining the best achievable outcome at an acceptable level of risk.
When this happens in other areas of medicine, we do not declare that the patient has failed because antibiotics remain on the medication list. Medicine recognizes the need for continued treatment as a consequence of the underlying clinical problem.
The Missing Question: Can Treatment Help Without Curing?
This raises a question that persistent Lyme research has not adequately answered: could there be patients for whom antimicrobial treatment is clinically useful without being curative?
The randomized trials do not show that persistent Borrelia infection definitely creates such a population. But the response patterns reported in STOP-LD and Fallon make the question scientifically reasonable. The registry data suggest that large numbers of patients are already pursuing extended treatment. Instead of allowing the argument to remain trapped between “everyone needs long-term antibiotics” and “nobody benefits from more antibiotics,” research should be designed to identify reproducible treatment-response phenotypes.
Who improves? In which symptom domains? How quickly? With which antimicrobial exposure? Does benefit persist after treatment withdrawal? If symptoms return, do they respond again to retreatment? Are there biomarkers associated with the pattern? And, crucially, can the same benefit be achieved with a safer strategy?
Those are answerable questions.
Are Antibiotics Sometimes Palliative?
The word palliative is uncomfortable in discussions of infectious disease because it sounds like surrender. We associate palliation with severe cancer, pain control or end-of-life care. In ordinary conversation, calling a treatment palliative can sound like admitting that the real problem has been abandoned.
Yet the broader medical concept is more useful than that. Palliation is concerned with reducing the burden of illness and improving quality of life even when treatment does not eliminate the underlying cause. A therapy may still carry clinical meaning without being curative.
Medicine is full of therapies whose benefits depend on continued exposure. Antiseizure medications may suppress seizures only while they are taken. Anti-inflammatory therapies can lose their benefit after discontinuation. Hormone replacement corrects a physiologic deficiency without necessarily eliminating the reason the deficiency developed. Losing a benefit after drug withdrawal does not, by itself, make the original response imaginary.
Why Antibiotics Require a Higher Bar
Antibiotics are different because their traditional purpose is antimicrobial eradication and because indiscriminate antibiotic exposure carries consequences that extend beyond the individual patient. Antimicrobial resistance is a population-level concern as well as a personal one. That difference deserves serious weight.
But it does not eliminate the question.
What Do We Call a Reproducible, Treatment-Dependent Benefit?
Imagine an antimicrobial regimen that repeatedly produces measurable improvement in fatigue, cognition, pain, skin disease or physical functioning. The patient still does not achieve a durable cure. Then symptoms predictably worsen after treatment withdrawal and improve again when a clinician carefully supervises retreatment.
What should we call that?
Curative treatment clearly does not fit if durable resolution never occurs. Suppressive antimicrobial therapy may be the more precise term if an ongoing infectious process researchers demonstrate it. Symptom-modifying therapy may fit better when the mechanism remains uncertain.
But perhaps, in some cases, the treatment is functionally palliative: it reduces suffering and maintains function without eliminating the biological process responsible for the illness.
I do not think medicine should be afraid to ask that question. I think it should be afraid of answering it without evidence.
The appropriate response is not to prescribe indefinite antibiotics to anyone with unexplained fatigue, pain or cognitive symptoms. A subjective response to treatment cannot substitute for diagnostic investigation, and prolonged therapy can cause real harm. The appropriate response is to design studies capable of measuring treatment-dependent quality-of-life effects rather than assuming that lack of cure automatically means lack of clinical value.
There Is More Than One Kind of Freedom
I have been on antibiotics for years.
That is not a statement I make with pride or shame. It is simply part of my medical history.
I understand the desire to be finished with them. After enough prescriptions, medication becomes a recurring reminder of illness. You begin to wonder what years of treatment are doing to your body. Every gastrointestinal symptom, unusual laboratory result and change in how you feel can trigger another question. Is the medication helping, harming or somehow doing both at once? Most of all, you wonder whether you will ever reach a point where treatment is no longer necessary.
For that reason, I understand why becoming “antibiotic-free” can feel like freedom.
Function Is a Form of Freedom
But illness teaches people that freedom has other definitions.
There is the freedom to work without spending the next two days recovering. You may be able to read a page and retain what it said, make plans without first calculating the physical cost, or simply sleep. Freedom can also mean moving through the day without pain occupying the center of every decision and participating in your own family and, more fundamentally, in your own life.
For one patient, stopping antibiotics may represent genuine and sustained recovery. For another, the same medication change may trigger a progressive loss of function. Those are not equivalent clinical outcomes merely because both charts eventually contain the phrase “antibiotics discontinued.”
When Treatment Duration Becomes a Moral Judgment
This is where our language can become unintentionally cruel. Patients who remain in treatment sometimes absorb the idea that they have failed to reach the next stage of recovery. We turn the person who stops medication into the success story. Meanwhile, we may label the person who continues treatment as complicated, dependent, noncompliant with the preferred narrative or simply “chronic.”
Yet chronic disease is full of patients who continue treatment because stopping treatment makes them worse.
A patient who requires six years of therapy is not morally inferior to a patient who recovered after six weeks. A patient who relapses has not necessarily failed to think positively, detoxify correctly, eliminate the correct food, take the right supplement or emotionally “move on” from being sick.
Perhaps the treatment failed to cure the underlying disease. The original diagnosis may have been incomplete, or infection, immune dysregulation, tissue injury or another disease process may still contribute. Medicine may also be compressing biologically distinct subgroups into one diagnostic category.
Or perhaps a subset of patients genuinely experiences an antimicrobial-dependent improvement that medicine has not yet learned to predict or explain.
All of these are hypotheses.
Shame is not a hypothesis.
A patient who still requires treatment has not failed.
Morgellons Patients Are Living Inside This Research Gap
This question matters especially in Morgellons disease, where many patients already have experience with antimicrobial treatment but controlled treatment data remain remarkably limited.
Published Morgellons literature includes reports describing improvement during antibiotic treatment. A 2021 case report, for example, described rapid symptomatic improvement after doxycycline and clearing of lesions by the end of a two-month treatment period. Other Morgellons researchers have proposed associations between the condition and borrelial infection, while competing literature continues to dispute the infectious interpretation of the disease.
A case report is not a randomized trial. Improvement in one patient cannot establish the expected response of a population, determine optimal treatment duration or prove that doxycycline acted through eradication of a specific organism.
This is precisely the problem.
We do not have a well-designed randomized trial that tells us whether antimicrobial treatment improves Morgellons disease, which patients are most likely to respond, how long treatment should continue or what happens after treatment is withdrawn. Current clinical literature cannot answer those questions with confidence.
Patients Are Already Generating the Data We Are Failing to Measure
Meanwhile, patients continue to be treated.
Some report improvement, while others relapse or remain ill despite extensive antimicrobial therapy. Adverse effects, cost, loss of access, or lack of benefit lead still others to stop treatment. Others remain on antibiotics for years because they believe—rightly or wrongly—that treatment is helping them preserve function.
We urgently need better ways to separate these experiences.
A meaningful Morgellons treatment study should do more than photograph the skin at baseline and again twelve weeks later. It should measure lesion burden and filament production, but it should also measure pain, sleep, fatigue, cognitive function, physical function and ability to work. Researchers should document antibiotic exposure precisely rather than reduce it to a checkbox asking whether a patient has “ever taken doxycycline.”
Study the Trajectory, Not Just the Endpoint
Most importantly, the study should examine the trajectory of illness.
What happens before treatment? During therapy, which symptoms change and does improvement plateau? After withdrawal, what occurs next? If symptoms return, how quickly do they return, and does retreatment reproduce the previous response?
The Fallon trial demonstrates why this temporal information matters. A study that examined cognition only months after treatment ended could conclude that ceftriaxone produced no durable cognitive advantage. That conclusion would be correct with respect to sustained benefit. It would also miss the fact that a treatment-associated cognitive improvement had occurred and was subsequently lost.
For Morgellons patients, who frequently describe years of waxing and waning illness, treatment changes and recurrent skin findings, studying only one distant endpoint may be particularly inadequate.
If a subgroup demonstrates reproducible improvement during antimicrobial treatment and deterioration after withdrawal, that pattern deserves investigation. Researchers should not automatically declare that pattern proof of persistent infection, but they should not dismiss it simply because the improvement failed to become permanent.
Study the pattern. Find out who experiences it. Find out why.
The Risk of Treatment Is Only Half of a Risk-Benefit Analysis
Any serious article about prolonged antibiotics has to address harm.
The Fallon trial documented real adverse events. Six of 23 ceftriaxone-treated patients experienced events related to the medication or PICC line. Antibiotic toxicities vary by drug and can range from gastrointestinal effects to allergic reactions, organ toxicity, drug interactions and serious infection with organisms selected by antimicrobial exposure. Intravenous access introduces another category of risk entirely.
These concerns are legitimate, and pretending otherwise does a disservice to patients considering treatment.
Untreated Illness Also Carries Risk
However, a genuine risk-benefit analysis has two sides.
Medicine often quantifies intervention risk well because researchers can count adverse events. We can calculate the number of line infections, treatment discontinuations or abnormal laboratory results.
Researchers have a harder time compressing the harms of uncontrolled chronic illness into an adverse-event table.
How do we calculate the medical cost of losing the ability to work? What is the consequence of severe cognitive dysfunction in a person attempting to maintain a career? How much harm is created by years of disabling fatigue, chronic pain or recurrent skin disease? What happens to physical conditioning, social isolation, income and mental well-being when a patient spends another year largely confined to home?
These are not arguments for ignoring antibiotic risk. They are arguments for completing the equation.
The Patient’s Decline Belongs in the Calculation
If stopping a risky treatment leaves a patient equally well, the risk may be easy to avoid.
If stopping treatment is followed by a substantial and reproducible deterioration in measurable function, the decision becomes more complicated. The treatment may still be too dangerous. Clinicians may need a safer alternative or may need to reconsider the diagnosis.
But the decline in the patient’s health belongs in the calculation.
An empty prescription bottle is not, by itself, a clinical endpoint.
Perhaps We Have Been Asking the Wrong Question
For years, debates over persistent Lyme-associated illness have focused on antibiotic duration: two weeks, four weeks, three months, one year. Duration matters, but it may be an imperfect way to organize the scientific problem.
Perhaps the better unit of analysis is the individual treatment-response trajectory.
Which patient improves, and in what domain? How large is the benefit, and can researchers measure it objectively? Does it persist after treatment withdrawal? Finally, what biological characteristics distinguish that patient from someone who receives the same therapy and experiences no benefit?
Better Measurement Could Support Either Conclusion
This approach would not guarantee that long-term antibiotic treatment emerges as the answer. Better measurement might reveal that many perceived responses do not withstand controlled testing. It might identify subgroups whose symptoms are driven by noninfectious mechanisms and who need completely different therapies. It might demonstrate that treatment-related harm exceeds benefit for certain patients.
But it could also reveal patients in whom continued antimicrobial therapy produces a meaningful, reproducible improvement in quality of life.
We should be willing to discover that too.
The Question Medicine Should Ask Instead
Perhaps the wrong question has been, “How do we get these patients off antibiotics?”
A better question may be: “What treatment strategy gives this individual the greatest sustained function and quality of life at the lowest acceptable risk?”
Sometimes the answer will be no antibiotics. Patients who complete treatment and remain well may gain no reasonable benefit from continued antimicrobial exposure.
In other cases, the risks of additional treatment will clearly outweigh any measurable improvement.
Yet after weighing measurable benefit against known risk, clinicians may sometimes conclude that the answer is continued antibiotics.
That possibility should not be treated as a failure of medicine simply because treatment is suppressive, symptom-modifying or palliative rather than curative. Nor should anyone make the patient feel that needing continued treatment represents a personal failure to recover.
Medicine should arrive at these decisions by measuring the patient: their physical function, cognition, pain, fatigue, skin disease, quality of life, adverse effects and response when treatment is started or withdrawn.
Not by celebrating an empty prescription bottle.
Being free of antibiotics is not the same thing as being free of disease.
And a patient who still needs treatment should never be made to feel ashamed for wanting the freedom to live.
References and Further Reading
- Johnson L, Shapiro M, Stricker RB, Vendrow J, Haddock J, Needell D. Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not? Healthcare. 2020;8(4):383.
- Klempner MS, Hu LT, Evans J, et al. Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease. New England Journal of Medicine. 2001;345(2):85–92.
- Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. New England Journal of Medicine. 2016;374:1209–1220.
- Krupp LB, Hyman LG, Grimson R, et al. Study and Treatment of Post Lyme Disease (STOP-LD): A Randomized Double Masked Clinical Trial. Neurology. 2003;60(12):1923–1930.
- Fallon BA, Keilp JG, Corbera KM, et al. A Randomized, Placebo-Controlled Trial of Repeated IV Antibiotic Therapy for Lyme Encephalopathy. Neurology. 2008;70(13):992–1003.
- Sandiford NA, Hutt JR, Kendoff DO, Mitchell PA, Citak M, Granger L. Chronic Antibiotic Suppression for Prosthetic Joint Infections. PubMed-indexed clinical research on selected patients managed with chronic antimicrobial suppression.
- Du CM, Kalbermatten DF, de Viragh PA, et al. Morgellons Disease: A Case Report. Published case literature describing improvement during doxycycline treatment.
This article is intended for education and patient advocacy. It does not recommend self-directed antibiotic treatment and is not a substitute for individualized medical care. Prolonged and intravenous antibiotic therapies can cause serious adverse effects and require appropriate medical assessment, monitoring and supervision.
